NeuroSense Therapeutics Ltd. (NRSN) Form 6-K — Oct 13, 2026
NeuroSense Therapeutics announced its Nasdaq Hearings Panel hearing is scheduled for November 10, 2026, following its timely appeal of the October 1, 2026 Staff Delisting Determination. Shares and warrants continue trading under NRSN and NRSNW pending the Panel's decision. The company has already regained compliance with Nasdaq's $1.00 minimum bid price requirement; the sole remaining deficiency is the $35 million minimum market value of listed securities standard. NeuroSense will present a compliance plan and request an exception period of up to 180 days, with no assurance of approval.
Key figures
- Als disease burden
- $1 billion annually
- Nasdaq hearing date
- 2026-11-10
- Als annual us diagnoses
- more than 5,000
- Minimum mvls requirement
- $35 million
- Staff determination date
- 2026-10-01
- Maximum panel exception period
- 180 days
- Grant funding decision expected
- Q1 2027
- Health canada submission target
- December 2026
- Alternative stockholders equity standard
- $2.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.